Adimmune Corp
TWSE:4142

Watchlist Manager
Adimmune Corp Logo
Adimmune Corp
TWSE:4142
Watchlist
Price: 19.3 TWD -2.28% Market Closed
Market Cap: NT$8.3B

Relative Value

The Relative Value of one Adimmune Corp stock under the Base Case scenario is hidden TWD. Compared to the current market price of 19.3 TWD, Adimmune Corp is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Adimmune Corp Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Adimmune Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
TW
Adimmune Corp
TWSE:4142
8.1B TWD 6.8 -16 -24 -15.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 746 422.5 -160 391.7 -165 649.1 -163 758.9
US
Abbvie Inc
NYSE:ABBV
385B USD 6.5 164 15.9 22.6
US
Amgen Inc
NASDAQ:AMGN
184.4B USD 5.1 26.3 18.8 18.8
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD 5.8 20.8 14.1 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD 10.1 32.2 23.6 24.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 087.6 -532.7 -682 -663.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD 5.6 17.3 16.5 18.7
AU
CSL Ltd
ASX:CSL
87B AUD 3.8 19.8 9.1 11.3
NL
argenx SE
XBRU:ARGX
43.2B EUR 14.1 33.1 67 68.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD 14.9 1 097.6 147.9 179.4
P/S Multiple
Revenue Growth P/S to Growth
TW
Adimmune Corp
TWSE:4142
Average P/S: 3 068 053
6.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 746 422.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.8
4%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.1
10%
1
US
E
Epizyme Inc
F:EPE
2 087.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
14.1
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.9
46%
0.3
P/E Multiple
Earnings Growth PEG
TW
Adimmune Corp
TWSE:4142
Average P/E: 176.4
Negative Multiple: -16
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 391.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
164
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
26.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
20.8
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
10%
1.7
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
33.1
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 097.6
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
TW
Adimmune Corp
TWSE:4142
Average EV/EBITDA: 39.1
Negative Multiple: -24
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 649.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.8
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
7%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -682 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
9.1
8%
1.1
NL
argenx SE
XBRU:ARGX
67
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
147.9
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
TW
Adimmune Corp
TWSE:4142
Average EV/EBIT: 44.8
Negative Multiple: -15.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 758.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
12%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.7
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -663.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
11.3
11%
1
NL
argenx SE
XBRU:ARGX
68.9
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
179.4
N/A N/A